McMaster University spinout Fusion Pharmaceuticals has filed for a $100m IPO in the US, putting shareholders such as Facit in line for exits.

Fusion Pharmaceuticals, a Canada-based cancer radiopharmaceuticals developer spun out of McMaster University, has filed for a $100m initial public offering on the Nasdaq Global Market.
The company has not yet settled on a price range or determined the number of shares it will issue.
Founded in 2014, Fusion Pharmaceuticals is developing targeted alpha therapeutics, a type of cancer treatment that relies on equipping molecules, such as antibodies, with radioactive particles – called alpha emitting medical isotopes –…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in